Phase I study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult B-ALL patients.
Gauthier J, Liang EC, Huang JJ, Kimble EL, Hirayama AV, Fiorenza S, Voutsinas JM, Wu QV, Jaeger-Ruckstuhl CA, Pender BS, Kirchmeier DR, Torkelson A, Braathen K, Basom R, Shadman M, Kopmar NE, Cassaday RD, Riddell SR, Maloney DG, Turtle CJ.
Gauthier J, et al. Among authors: wu qv.
Blood Adv. 2025 Jan 16:bloodadvances.2024015314. doi: 10.1182/bloodadvances.2024015314. Online ahead of print.
Blood Adv. 2025.
PMID: 39820359